ReviewClinical journal of the American Society of Nephrology : CJASN2014
Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.
Review in Clinical journal of the American Society of Nephrology : CJASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Interference of Immunosuppressive Therapies with Cellular Antimicrobial Activity AgainstInternational journal of molecular sciences · 2026Article
- Systematic Review of Efficacy and Safety of Avacopan in Real-World Clinical Practice.Kidney international reports · 2026Article
- Expert review and recommendations on the diagnosis and therapeutic management of eosinophilic granulomatosis with polyangiitis.Frontiers in immunology · 2026Review
- Association between body mass index and severe infection in older adults with microscopic polyangiitis: a retrospective cohort in Japan.BMC geriatrics · 2021Article
- Renal biopsy in very elderly patients (over 80 years): clinical presentation, histological diagnosis, and long-term outcome.International urology and nephrology · 2020Observational
- Rituximab use in adult glomerulopathies and its rationale.Jornal brasileiro de nefrologia · 2020Review
- Infectious complications of rituximab therapy in renal disease.Clinical kidney journal · 2017Article
- Cathepsin S inhibition combines control of systemic and peripheral pathomechanisms of autoimmune tissue injury.Scientific reports · 2017Article
- Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis.Frontiers in immunology · 2017Article
- Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Review
- Glomerular Diseases: Registries and Clinical Trials.Clinical journal of the American Society of Nephrology : CJASN · 2016Article
- Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical outcomes in ANCA-associated vasculitis (AAV) and lupus nephritis have improved greatly with treatment regimens containing high-dose glucocorticoids and cyclophosphamide. However, with the use of these medications come significant adverse events, most notably infections, cytopenias, malignancies, and reproductive abnormalities. Multiple recent randomized controlled trials in AAV and lupus nephritis have compared cyclophosphamide-based regimens with agents such as rituximab, mycophenolate mofetil, and azathioprine, with the hope of providing better clinical outcomes with improved safety profiles. Although some of these newer regimens are now considered first-line treatments of these diseases, their adverse event profiles have been disappointingly similar to those of cyclophosphamide-based protocols. Physicians and patients should consider the adverse event profiles generated by these trials in the context of their extensive use in other patient populations, as well as available measures to prevent such events, when choosing the ideal regimen for an individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.